Combination Low-Dose Tissue-Type Plasminogen Activator Plus Annexin A2 for Improving Thrombolytic Stroke Therapy.
Combination Low-Dose Tissue-Type Plasminogen Activator Plus Annexin A2 for Improving Thrombolytic Stroke Therapy.
复制标题
DOI：
10.3389/fncel.2015.00397
复制
发表时间：
2015
影响因子：
5.3
通讯作者：
Wang X
中科院分区：
文献类型：
--
作者：
Jiang Y;Fan X;Yu Z;Liao Z;Wang XS;van Leyen K;Sun X;Lo EH;Wang X
出血性转化、不完全再通、神经毒性和短治疗时间窗口的风险构成了组织纤溶酶原激活剂(TPA)溶栓治疗卒中治疗的主要挑战。改善tPA治疗已成为卒中领域的首要任务之一。这篇简短的综述文章集中于我们最近的努力，旨在评估一种新的联合应用小剂量tPA和重组膜联蛋白A2(RA2，tPA和纤溶酶原共受体)的方法，该方法可以增强tPA的溶栓效果，同时减少与脑出血转化相关的并发症。我们在大鼠局灶性栓塞性卒中模型上的实验研究结果支持联合方法的可行性，并暗示了成功的临床移植的潜力。
Risk of hemorrhagic transformation, incomplete reperfusion, neurotoxicity, and a short treatment time window comprises major challenges for tissue plasminogen activator (tPA) thrombolytic stroke therapy. Improving tPA therapy has become one of the highest priorities in the stroke field. This mini review article focuses on our recent efforts aimed at evaluating a novel combination approach of low-dose tPA plus recombinant annexin A2 (rA2, a tPA, and plasminogen co-receptor), which might enhance tPA thrombolytic efficacy, while reducing its associated complications related to intracerebral hemorrhagic transformation. Results of our experimental studies using a focal embolic stroke model in rats support the feasibility of the combination approach and suggest the potential for successful clinical translation.